This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2008;299(2):157-158.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Two decades of inadequate funding have rendered the Food and Drug Administration's (FDA’s) scientific capacity insufficient to meet the growing demands of ensuring the public's health and safety, according to a report issued in December by an advisory group to the agency.

Advances in science, greater complexity in the products it regulates, and globalization of FDA-regulated industries are among the trends placing unprecedented demands on the FDA, yet resources for the agency's science infrastructure and staff have been stagnant, according to the 300-page report (http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf).

Underinvestment has left the Food and Drug Administration with outdated technology and other problems that interfere with its duty to protect the public’s food and medical supplies.

The report was published by a subcommittee of the FDA Science Board, which advises FDA Commissioner Andrew C. von Eschenbach, MD, and convened the subcommittee at his request. The report, which took 1 . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?